SFD

Growing the top line

We maintain a BUY recommendation on SFD and cut our FV from PLN 6.50 to PLN 5.51 per share. In 9M21 the company reported a net profit of PLN 10.9m (vs. PLN 9.8m reported in 9M20). Although revenues increased at that time by nearly 24% y/y and gross margin improved by 1.3pp y/y, operating margin was negatively affected by higher costs of materials and external services. In FY2021E we forecast SFD to reach revenues of PLN 242m (upgraded by 3%) and EBIT of PLN 17m (forecast down by 10%), while given sound top line growth (driven by the dietary nutrition segment and foreign expansion), we slightly upgrade our forecasts for FY2022E with revenues of PLN 282m and EBIT cut by 10% to PLN 20m. On our forecasts, SFD currently trades at a P/E of 13.1x in 2021E and PLN 10.5m in 2022E, while assuming a 30% payout ratio, we expect DPS of PLN 0.09/share from 2021E results (including proposed PLN 0.04/share of an advance dividend) and PLN 0.11/share from 2022E results.

Growing scale of operations...

SFD reported 24% y/y growth of revenues in 9M21 (to PLN 184m). In the coming quarters, we expect the trend to be maintained and top line to be driven by growth of the dietary nutrition segment (in line with the market) and development of sales in foreign markets (already launched in Czechia and Slovakia). As a result, we slightly increase our forecasts to PLN 282m in 2022E (+17% y/y) and PLN 318m in 2023E (+13% y/y).

... supporting margins expansion

We note that the increasing scale of operations together with a more favourable sales mix (increasing the share of its own brand products) should support improvement in gross margins by SFD. Although profitability might be under pressure on increasing costs of materials and the USDPLN rate, we expect SFD to transfer the majority of the above-mentioned on to the final customer. As a result, we forecast gross margins to improve from 35.1% in 2020 to 35.8% in 2021E and 36.0% in 2022E. At the same time, we highlight increasing minimum wages and expansion on foreign markets to have a negative impact on profitability, though operating leverage should allow for slight improvement in 2022E.

Valuation and dividend policy

On our forecasts SFD currently trades at a P/E of 13.1x in 2021E and 10.5x in 2022E. In our forecasts, we assume a 30% payout ratio, implying a DPS of PLN 0.09/share from 2021E net profit (including PLN 0.04/share proposed as an advance dividend) and PLN 0.11/share from 2022E results (DY of 2.3% and 2.9%, respectively).

Figure 1. SFD – Financial summary (PLNm)

	2019	2020	2021E	2022E	2023E	2024E
Revenues	142.3	196.9	241.9	282.4	318.3	349.6
EBITDA	5.5	16.6	19.2	24.2	28.7	32.3
EBIT	3.9	14.7	16.6	20.3	22.2	22.8
Net profit	2.4	11.5	13.1	16.3	17.5	18.1
P/E (x)	5.5	14.2	13.1	10.5	9.8	9.5
P/BV (x)	4.9	10.6	9.1	6.9	6.5	5.7
DPS (PLN)	0.00	0.04	0.06	0.09	0.11	0.12


Source: Company, IPOPEMA Research

Retail

SFD

BUY FV PLN 5.51 from PLN 6.50 41% upside

Price as of 9 December 2021 PLN 3.90 BUY maintained



Share data

Number of shares (m)	44.0
Market cap (EUR m)	37.2
12M avg daily volume (k)	17.7
12M avg daily turnover (EUR m)	0.02
12M high/low (PLN)	6.28/2.96
WIG weight (%)	n.a.
Reuters	SFDP.WA
Bloomberg	SFD PW

Total performance	
1M	-15.8%
	06.404

3M	-26.1%
12M	24.6%

Shareholders

Mateusz Dominik Pazdan	76.24%
Other	23.76%

Analyst

Marek Szymański marek.szymanski@ipopema.pl + 48 22 236 94 12

2020 2021E 2022E 2023E 2024E

2019

BUY FV PLN 5.51 Operating costs DBA mkt Cap EUR 37m Upside 41% Cost of materials and energy. External services Valuation multiples 2020 2021E 2022E 2023E 2024E Valuation multiples 2020 2021E 2022E 2023E 2024E Valuation multiples 2020 2021E 2022E 2023E 2024E PVE (x) 7.5 4.12 3.18 2.58 Cost of goods sold PVS (w) 7.54 4.12 3.18 2.58 Cost of goods sold PYG (w) 7.54 4.12 3.15 1.14% -2.38 1.01% No. of share(m units) 4.22 4.04 4.40 4.40 Monetax PYS (PLN) 0.25 0.30 0.37 0.40 0.41 BVS (PLN) 0.22 0.30 0.37 0.40 0.41 BVS (PLN) 0.52 0.21E 2022E 2023E 2024E 11 Income tax BVS (PLN) 0.52 0.21E </th <th>SFD</th> <th></th> <th></th> <th></th> <th></th> <th></th> <th>P&L (PLN m) Revenues</th>	SFD						P&L (PLN m) Revenues
Link Cap EUR 37m Upside 41% DBA Valuation multiples 2020 2021E 2022E 2023E 2024E Salaries Social benefits 54 13.1 10.5 9.8 9.5 Other operating costs Social benefits PVF (x) 10.6 9.1 6.9 6.5 5.7 Cost of goods sold PVS (y) 7.54 1.2 3.18 2.58 2.57 Cost of goods sold DY (w) 7.54 1.2 3.18 2.58 Cost of poods sold Per share 2020 2021E 2022E 2023E 2024E No. of shares (m units) 4.22 4.40 4.40 4.40 No. Per share 2020 20.21E 2022E 2023E 2024E Income tax No. of shares (m units) 4.22 4.04 4.40 4.04 No. No. No. Social mode (nat margine) DPS (PLN) 0.52 0.95 1.23 1.51 1.11 Income tax <t< td=""><td>BUV</td><td></td><td></td><td></td><td></td><td>5 5 1</td><td></td></t<>	BUV					5 5 1	
Valuation multiples 2020 2021E 2022E 2024E Social benefits P/E (x) 14.2 13.1 10.5 9.8 50 Other operating costs EV/SellDA (x) 10.6 9.1 6.9 6.5 5.7 Cost of goods soid EV/SellS (x) 0.9 0.7 0.6 0.65 5.7 Cost of goods soid PKP (x) 7.412 3.18 2.58 2.024E EBIT Financial income (cost) net PYE (x) 1.3% 1.5% 2.3% 2.024E D242E Prestamp of (1) DY(%) 0.75 0.20 0.30 0.37 0.40 0.40 BVS (PLN) 0.25 0.50 0.62 0.022 2024E Code/Will and intangible asset PR& DSP (PLN) 0.36 0.20 0.43 -0.11 0.30 O.04 DSP (PLN) 0.35 0.20 2022E 2024E 2024E Current assets Everues 38.3% 22.8% 16.8% 12.7% 9.8% <td>вот</td> <td></td> <td></td> <td>Г</td> <td></td> <td></td> <td>D&A</td>	вот			Г			D&A
Valuation multiples 2020 2021E 2022E 2023E 2024E Solaries P/E (x) 14.2 13.1 10.5 9.8 9.5 Other operating income/cost P/E (x) 10.6 9.1 6.0 6.05 5.7 Cost of goods sold P/E/W (x) 7.51 4.12 3.18 2.28 2.16 EBITDA P/E/W (x) 7.51 1.55 2.28 2.024E 2024E 2024E 10.000 10.11 P/E share 2020 2021E 2022E 2023E 2024E 10.000 10.11 10.000 10.01 P/S (PLN) 0.52 0.03 0.33 0.04 0.44 44.0<	mkt Cap EUR 37m				Upsi	de 41%	Cost of materials and energy
Valuation multiples 2020 2021E 2022E 2021E Social benefits VE/E (x) 10.6 9.1 6.9 6.5 5.7 Cost of goods sold EV/Sales (x) 0.9 0.7 0.6 0.6 0.5 0.57 Cost of goods sold PV/Sales (x) 9.3% 5.1% 11.1% -3.2% 10.1% EBIT DA PCW (x) 7.51 4.12 2.3% 2.9% 3.1% Financial income (cost) net PY(y) 1.3% 1.5% 2.3% 2.04 4.0 4.0 4.0 Homore tax No. of shares (m units) 42.2 44.0 44.0 4.00 0.01 DD Pre-tax profit Income tax Net profit EBIT Non-current assets Coddwill and intangible asset PRAC Net profit 2.2 2.02 2.02 Coll Non-current labilition							
Valuation multiples 2020 2021E 2022E 2023E 2024E Social benefits P/E (k) 14.2 13.1 10.5 9.8 9.5 Other operating costs EV/Sales (x) 0.9 0.7 0.6 0.6 0.5 Other operating income/cost F/EW (x) 7.51 4.12 3.18 2.58 2.16 EBITDA P/EW (x) 7.51 4.12 3.18 2.58 2.16 EBIT P(%) 1.3% 1.5% 2.3% 2.9% 3.1% Financial income (cost) net P/EV (%) 0.32 0.221E 2022E 2023E 2024E Honone tax Non-current assets 0.05 0.06 0.99 0.11 0.18 Non-current assets Goodwill and intangible asset PPAE Current assets Godwill and intangible asset Revenues 38.3% 228.% 16.8% 2.7% Non-current assets Grage y/y (%) 2022 2022E 2023E 2024E Inventories							
PFE (x) 14.2 13.1 10.5 9.8 9.5 Other operating income/cost Cost of goods sold EVVEBIDA (x) 10.6 9.1 6.9 6.5 5.7 CVSales (x) 0.9 0.7 0.6 0.6 0.5 Der operating income/cost P/BV (x) 7.51 4.12 3.18 2.58 2.16 Per share 2020 2021E 2022E 2024E 10.1% No. of shares (m units) 4.22 4.40 44.0 44.0 44.0 BVP (PLN) 0.27 0.30 0.37 0.40 0.41 BVPS (PLN) 0.55 0.60 0.99 0.11 0.12 Change y/y (%) 2020 2021E 2022E 2022E 2024E Constance Change y/y (%) 2020 2021E 2022E 2022E 2024E Constance Current assets Revenues 38.3% 22.8% 16.8% 12.7% 9.8% Other ourent assets EBIT 274.7% <td< td=""><td>Valuation multiples</td><td>2020</td><td>2021F</td><td>2022F</td><td>2023E</td><td>2024F</td><td></td></td<>	Valuation multiples	2020	2021F	2022F	2023E	2024F	
EWEBITDA (x) 10.6 9.1 6.9 6.5 5.7 Cost of goods sold EV/Sales (x) 0.9 0.7 0.6 0.5 0.5 0.1 FUF (x) 7.51 4.12 3.18 2.58 2.16 EBITDA FCF yield (%) 9.3% 5.1% 11.1% -3.2% 10.1% EBITDA Per share 2020 2021E 2022E 2023E 2024E Income (cost) net	· · · · · · · · · · · · · · · · · · ·						
EV/Sales (x) 0.9 0.7 0.6 0.6 0.5 Other operating income/cost P/BV (x) 7.51 4.12 3.18 2.58 2.16 EBITDA DY (%) 1.3% 1.5% 2.3% 2.9% 3.1% Financial income (cost) net Per share 2022 2021E 2022E 2023E 2044 No. of shares (m units) 42.2 44.0 44.0 44.0 44.0 44.0 BYS (PLN) 0.52 0.95 0.40 0.41 BLANCE SHEET (PLN m) SCPS (PLN) 0.36 0.20 0.43 0.13 0.39 On-current assets BITDA 2052 N 15.2% 26.3% 18.7% 12.3% Current assets Change y/y (%) 2020 2021E 2022E 2023E 2024E Current assets BITDA 2052 N 15.2% 6.3% 8.6% 3.6% 2.5% Carrent assets BITDA 2052 N 15.2% 6.5% 7.1% 3.7%		10.6	9.1	6.9	6.5		
FCF yield (%) 9.3% 5.1% 11.1% -3.2% 10.1% EBIT DY (%) 1.3% 1.3% 2.3% 2.9% 3.1% Financial income (cost) net Per share 2020 2021E 2022E 2023E 2024E Income tax No. of shares (m units) 4.2.2 4.40 4.40 4.40 4.40 BYS (PLN) 0.52 0.95 1.2.3 1.51 1.81 BALANCE SHEET (PLN m) SCPS (PLN) 0.36 0.09 0.11 0.13 0.39 Ode ownit assets BUTDA 205.2% 15.2% 20.3% 18.7% 12.3% Current assets EBITD 205.4% 15.2% 2.3% 16.5% Total assets EBITD 204.7% 12.7% 2.9% Inventories Trade raceivables Cash and equivalents 36.3% 36.5% 36.3% 36.5% Total assets EBITD 77.5% 6.5% 5.5% 5.2% Provisions Net debt / Assets (0	EV/Sales (x)	0.9	0.7	0.6	0.6	0.5	-
DY (%) 1.3% 1.5% 2.3% 2.9% 3.1% Financial income (cost) net Pre-tax profit income tax Per share 2020 2021E 2022E 2024E 2024E 2024E No. of shares (m units) 4.2.2 4.4.0 44.0 44.0 44.0 44.0 44.0 BVPS (PLN) 0.52 0.95 1.31 1.81 BALANCE SHEET (PLN m) DYS (PLN) 0.05 0.06 0.09 0.11 0.12 Goodwill and intangible asset PP&E Change y/y (%) 2020 2021E 2022E 2023E 2024E Current assets BIT 274.7% 1.2% 2.9% 3.1% 2.5% Current assets Cors margin (%) 3.5% 7.9% 8.6% 9.0% 9.2% BIT margin (%) 7.5% 6.9% 7.2% 2.7% 7.1% 3.7% Net debt / EBITDA (x) 0.75 0.15 -0.16 0.53 0.34 Current assets BIT margin (%) 7.5% 6.9% 7.2%	P/BV (x)	7.51	4.12	3.18	2.58	2.16	EBITDA
Per share 2020 2021E 2022E 2023E 2024E Income tax No. of shares (m units) 42.2 44.0 44.0 44.0 44.0 44.0 PS (PLN) 0.27 0.30 0.37 0.40 0.41 BVPS (PLN) 0.52 0.95 1.23 1.51 1.81 BCPS (PLN) 0.05 0.06 0.09 0.11 0.12 Goodwill and intangible asset PS (PLN) 0.05 0.06 0.09 0.11 0.12 Goodwill and intangible asset Revenues 38.3% 22.9% 16.8% 12.7% 9.8% Other non-current assets EBITD 274.7% 12.7% 2.03E 2024E	FCF yield (%)	9.3%	5.1%	11.1%	-3.2%	10.1%	EBIT
Per share 2020 2021E 2022E 2023E 2024E Income tax No. of shares (m units) 42.2 44.0 44.0 44.0 44.0 EPS (PLN) 0.27 0.30 0.37 0.40 0.41 BVPS (PLN) 0.35 0.20 0.43 0.33 0.39 DPS (PLN) 0.05 0.06 0.09 0.11 0.12 Change y/y (%) 2020 2021E 2022E 2023E 2024E EBITDA 205.29 15.23 15.74 12.35 Inventories EBITDA 207.47% 12.7% 21.9% 9.4% 2.9% Net profit 37.41% 35.6% 3.6% 3.7% 3.7% EBITDA 202.0 2021E 2022E 2024E Cash and equivalents Carsor smargin (%) 35.5% 5.2% Non-current assets Total assets EBIT margin (%) 5.9% 5.4% 5.5% 5.2% Non-current liabilities Revenues 19	DY (%)	1.3%	1.5%	2.3%	2.9%	3.1%	Financial income (cost) net
No. of shares (m units) 42.2 44.0 44.0 44.0 44.0 44.0 EPS (PLN) 0.27 0.30 0.37 0.40 0.41 BVPS (PLN) 0.52 0.95 1.23 1.51 1.81 FCPS (PLN) 0.05 0.06 0.09 0.11 0.12 Change y/y (%) 2020 2021E 2022E 2023E 2024E Revenues 38.3% 22.8% 16.8% 12.7% 9.8% EBITD 274.7% 12.7% 21.9% 9.4% 2.9% Net profit 374.1% 13.6% 2.45.% 7.1% 3.7% Coross margin (%) 35.1% 35.8% 5.5% 5.2% Non-current assets Coross margin (%) 5.9% 5.9% 5.5% 5.2% Non-current liabilities Net debt / Asset (x) 0.23 0.04 -0.04 0.11 0.08 ROE (%) 24.9% 19.9% 48.9% 24.8% Current liabilities Rocos (%)							Pre-tax profit
EPS (PLN) 0.27 0.30 0.37 0.40 0.41 BVPS (PLN) 0.52 0.95 1.23 1.51 1.81 PCFPS (PLN) 0.05 0.06 0.09 0.11 0.12 Godwill and intangible asset P8.E Change y/y (%) 2020 2021E 2022E 2023E 2024E Change y/y (%) 25.2% 15.3% 13.7% 12.3% Current assets EBITD 274.7% 12.7% 21.9% 9.4% 2.9% Inventories Trade receivables Cash and equivalents Leverage and return 2020 2021E 2022E 2023E 2024E Other non-current assets Gross margin (%) 35.1% 35.8% 36.0% 36.3% 36.5% Fouriert assets Rot det / EDIDA (x) 0.75							Income tax
BVPS (PLN) 0.52 0.95 1.23 1.51 1.81 BALANCE SHEET (PLN m) FCFPS (PLN) 0.36 0.20 0.43 -0.13 0.39 DPS (PLN) 0.05 0.06 0.09 0.11 0.12 Goodwill and intangible asset PPSE E Codwill and intangible asset PPSE E Change y/y (%) 2020 2021E 2022E 2023E 2024E Linventories Revenues 38.3% 22.8% 16.8% 17.7% 9.8% Other non-current assets Other non-current assets BIT 274.7% 12.7% 21.9% 9.4% 2.9% Inventories Leverage and return 2020 2021E 2022E 2023E 2044 Dthe current assets Gross margin (%) 35.1% 35.8% 36.0% 36.3% 36.5% Equity EBIT margin (%) 7.5% 6.9% 7.2% 7.0% 6.5% Forvisions Net agein (%) 2.39 0.04 -0.016 0.53 0.34							Net profit
FCFPS (PLN) 0.36 0.20 0.43 -0.13 0.39 Non-current assets DPS (PLN) 0.05 0.06 0.09 0.11 0.12 Godwill and intangible asset Change y/y (%) 2020 2021E 2022E 2023E 2024E LT investments Change y/y (%) 205.2% 15.2% 26.3% 18.7% 12.3% Inventories BITDA 205.2% 15.2% 26.3% 18.7% 12.3% Inventories Net profit 374.1% 13.6% 24.5% 7.1% 3.7% Trade receivables Cash and equivalents 0ther current assets Trade receivables Cash and equivalents BITDA margin (%) 5.5% 5.9% 5.5% 5.2% Mon-current liabilities Net debt / EBITDA (x) 0.75 0.07 0.07 0.23 0.44 Loans and borrowings Net debt / Assets (x) 0.23 0.44 0.45% 15.4% 27.2% 21.4% Loans and borrowings ROC (%) 39.0% 34.3%							
DPS (PLN) 0.05 0.06 0.09 0.11 0.12 Change y/y (%) 2020 2021E 2022E 2022E 2024E LT Investments Revenues 38.3% 22.8% 15.2% 26.3% 12.7% 9.4% 2.9% EBITDA 205.2% 15.2% 26.3% 12.7% 9.4% 2.9% Inventories Trade receivables Trade receivables Current assets Cash and equivalents Leverage and returr 2020 2021E 2022E 2023E 2024E BIT margin (%) 5.1% 55.% 36.0% 36.3% S6.5% Equity BIT margin (%) 5.9% 5.4% 5.8% 5.5% 5.2% Monorties Net debt / EBITDA (x) 0.75 0.15 -0.16 0.53 0.34 Non-current liabilities ROE (%) 64.6% 41.3% 34.1% 28.9% 24.8% Current liabilities Rob (%) 24.9% 19.9% 18.0% 14.5% 12.9%							
Change y/y (%) 2020 2021E 2022E 2023E 2024E UT investments Revenues 38.3% 22.8% 16.8% 12.7% 9.8% EBITDA 205.2% 15.2% 26.3% 18.7% 12.3% EBIT 274.7% 12.7% 21.9% 9.4% 2.9% Inventories Inventories Inventories Current assets EBITDA 2020 2021E 2023E 2024E Other current assets Gross margin (%) 35.1% 35.8% 36.0% 36.3% 36.5% EBITDA margin (%) 5.9% 5.4% 5.8% 5.2% Frovisions Net debt / Equity (x) 0.75 0.07 -0.07 0.23 0.14 Non-current liabilities ROE (%) 24.9% 19.9% 18.0% 41.5% 12.9% Current liabilities Roe (%) 24.9% 19.9% 18.0% 41.5% 12.9% Current liabilities Roe (%) 24.9% 19.9% 18.0% 14.5% <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>							
Change y/y (%) 2020 2021E 2022E 2023E 2024E LT investments Revenues 38.3% 22.8% 16.8% 12.7% 9.8% Other non-current assets EBITD 274.7% 12.7% 21.9% 9.4% 2.9% Inventories Net profit 374.1% 13.6% 24.5% 7.1% 3.7% Leverage and returr 2020 2021E 2022E 2023E 2024E Gross margin (%) 35.1% 35.8% 36.0% 36.3% 36.5% Total assets EBITDA margin (%) 5.5% 5.2% 7.0% 6.5% Minorities Net debt / EBITDA (x) 0.75 0.15 -0.16 0.53 0.34 Net debt / Assets (x) 0.23 0.04 -0.07 0.23 0.14 Loans and borrowings Other non-current liabilities Current liabilities Current liabilities Current liabilities ROE (%) 24.9% 19.9% 18.0% 14.5% 12.9% Other non-current liabilities	DPS (PLN)	0.05	0.06	0.09	0.11	0.12	8
Revenues 38.3% 22.8% 16.8% 12.7% 9.8% Other non-current assets EBIT 274.7% 12.7% 21.9% 9.4% 2.9% Inventories Net profit 374.1% 13.6% 24.5% 7.1% 3.7% Trade receivables Leverage and return 2020 2021E 2022E 2023E 2024E Current assets EBIT margin (%) 35.1% 35.8% 30.0% 36.3% 36.5% Total assets EBIT margin (%) 5.9% 5.4% 5.8% 5.5% 5.2% Non-current labilities Net debt / Eguity (%) 0.75 0.15 -0.16 0.53 0.34 Net debt / Assets (x) 0.23 0.04 -0.04 0.10 0.08 ROE (%) 64.6% 41.3% 34.1% 28.9% 24.8% Current labilities Robel / Assets (x) 0.23 0.04 -0.04 0.10 0.08 Current liabilities Robel / Asset (%) 24.9% 13.0% 14.5% 1	Change v/v (%)	2020	2021E	2022E	2023E	2024E	
EBITDA 205.2% 15.2% 26.3% 18.7% 12.3% Current assets EBIT 274.7% 12.7% 21.9% 9.4% 2.9% Inventories Net profit 374.1% 13.6% 24.5% 7.1% 3.7% Trade receivables Cash and equivalents Leverage and return 2020 2021E 2022E 2023E 2024E Other current assets Gross margin (%) 35.1% 35.8% 36.0% 36.3% 36.5% Equity BITDA margin (%) 5.9% 5.4% 5.8% 5.5% 5.2% Non-current liabilities Net debt / Equity (x) 0.75 0.07 -0.07 0.23 0.34 Loans and borrowings Net debt / Assets (x) 0.23 0.04 -0.04 0.11 0.08 Current liabilities ROE (%) 64.6% 41.3% 34.1% 2.9% 24.8% Current liabilities ROE (%) 39.0% 34.2% 34.7% 27.2% 21.4% Current liabilities Roc (%							
EBIT 274.7% 12.7% 21.9% 9.4% 2.9% Inventories Net profit 374.1% 13.6% 24.5% 7.1% 3.7% Trade receivables Cash and equivalents Other current assets Leverage and return 2020 2021E 2022E 2023E 2024E Other current assets Gross margin (%) 35.1% 35.6% 36.3% 36.5% Total assets EBITDA margin (%) 5.5% 5.2% Minorities Provisions Net debt / EBITDA (x) 0.75 0.15 -0.16 0.53 0.34 Net debt / Assets (x) 0.23 0.04 -0.04 0.11 0.08 Other non-current liabilities ROE (%) 64.6% 41.3% 34.1% 28.9% 24.8% Current liabilities ROE (%) 24.9% 19.9% 18.0% 14.5% 12.9% Trade payables Loans and borrowings ROI (%) 24.9% 24.1% 27.2% 21.4% Current liabilities Gross data services 19.6.9 <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>							
Net profit 374.1% 13.6% 24.5% 7.1% 3.7% Trade receivables Leverage and return 2020 2021E 2023E 2024E Cash and equivalents Gross margin (%) 35.1% 35.8% 36.0% 36.3% 36.5% Total assets EBIT margin (%) 5.5% 7.9% 8.6% 9.0% 9.2% Fotal assets Net debt / Epuity (x) 0.75 0.15 -0.16 0.53 0.34 Non-current liabilities Net debt / Equity (x) 0.57 0.07 -0.07 0.23 0.14 Loans and borrowings Net debt / Assets (x) 0.23 0.04 -0.04 0.11 0.08 Current liabilities ROE (%) 24.9% 19.9% 18.0% 14.5% 12.9% Trade payables Loans and borrowings ROIC (%) 39.0% 324.2% 318.3 349.6 Gross debt (PLN m) Products and services 196.9 241.9 282.4 318.3 349.6 products and services 15.8%							
Leverage and return 2020 2021E 2022E 2023E 2024E Cash and equivalents Gross margin (%) 35.1% 35.8% 36.0% 36.3% 36.5% Total assets EBITDA margin (%) 7.5% 6.9% 7.2% 7.0% 6.5% Full Net margin (%) 5.9% 5.8% 5.5% 5.2% Provisions Net debt / EQUIty (x) 0.57 0.07 -0.07 0.23 0.14 Net debt / Assets (x) 0.23 0.04 -0.04 0.11 0.08 ROE (%) 64.6% 41.3% 34.1% 28.9% 24.8% Current liabilities ROE (%) 24.9% 19.9% 18.0% 14.5% 12.9% 21.4% ROIC (%) 39.0% 34.2% 34.7% 27.2% 21.4% Current liabilities Revenues 196.9 241.9 282.4 318.3 349.6 products and services 14.19 195.0 23.65 273.3 305.5 goads and material							
Gross margin (%) 35.1% 35.8% 36.3% 36.3% 36.5% Total assets EBITDA margin (%) 7.5% 6.9% 7.2% 7.0% 6.5% Net margin (%) 5.9% 5.4% 5.8% 5.5% 5.2% Net debt / EpiTDA (x) 0.75 0.15 -0.16 0.53 0.34 Net debt / Equity (x) 0.57 0.07 -0.07 0.23 0.14 ROE (%) 64.6% 41.3% 34.1% 28.9% 24.8% Current liabilities ROE (%) 64.6% 41.3% 34.7% 27.2% 21.4% Current liabilities Assumptions 2020 2021E 2022E 2023E 2024E Equity & liabilities Gross and materials 55.0 45.9 45.0 44.1 Current liabilities Revenues 196.9 241.9 282.4 318.3 349.6 goads and materials 50.1% 52.9% 93.0% 93.5% Dett (PLN m) Dext of materials and e 44.3%	•						Cash and equivalents
EBITDA margin (%) 8.5% 7.9% 8.6% 9.0% 9.2% Equity EBIT margin (%) 7.5% 6.9% 7.2% 7.0% 6.5% Minorities Net debt / EBITDA (x) 0.75 0.15 -0.16 0.53 0.34 Non-current liabilities Net debt / Equity (x) 0.57 0.07 -0.07 0.23 0.14 Loans and borrowings Net debt / Assets (x) 0.23 0.04 -0.04 0.11 0.08 Current liabilities ROE (%) 64.6% 41.3% 34.1% 28.9% 24.8% Current liabilities ROE (%) 39.0% 34.2% 34.7% 27.2% 21.4% Loans and borrowings ROIC (%) 39.0% 34.2% 34.7% 27.2% 21.4% Loans and borrowings goods and materials 196.9 241.9 282.4 318.3 349.6 goods and materials and e 44.3% 50.1% 52.0% 53.3% 54.4 D&A 1.0% 1.1% 1.4% <	Leverage and return	2020	2021E	2022E	2023E	2024E	Other current assets
EBIT margin (%) 7.5% 6.9% 7.2% 7.0% 6.5% Minorities Net margin (%) 5.9% 5.4% 5.8% 5.5% 5.2% Provisions Net debt / EBITDA (x) 0.75 0.15 -0.16 0.53 0.34 Loans and borrowings Net debt / Equity (x) 0.57 0.07 -0.07 0.23 0.14 Loans and borrowings ROE (%) 64.6% 41.3% 34.1% 28.9% 24.8% Current liabilities ROE (%) 64.6% 41.3% 34.7% 27.2% 21.4% Loans and borrowings Cotree (%) 34.2% 34.7% 27.2% 21.4% Loans and borrowings ROIC (%) 39.0% 34.2% 34.7% 27.9% 21.4% Loans and borrowings Gross debt (PLN m) products and services 141.9 195.0 236.5 273.3 305.5 goods and materials 55.0 46.9 45.9 45.0 44.1 D&A 1.0% 1.4% 2.1%	Gross margin (%)	35.1%	35.8%	36.0%	36.3%	36.5%	Total assets
Net margin (%) 5.9% 5.4% 5.8% 5.5% 5.2% Provisions Net debt / EBITDA (x) 0.75 0.15 -0.16 0.53 0.34 Non-current liabilities Net debt / Equity (x) 0.57 0.07 -0.07 0.23 0.14 Loans and borrowings Net debt / Assets (x) 0.23 0.04 -0.04 0.11 0.08 ROE (%) 64.6% 41.3% 34.1% 28.9% 24.8% Other non-current liabilities ROA (%) 24.9% 19.9% 18.0% 14.5% 12.9% Trade payables ROIC (%) 39.0% 34.2% 34.7% 27.2% 21.4% Loans and borrowings Assumptions 2020 2021E 2022E 2023E 2024E Equity & liabilities Revenues 196.9 241.9 282.4 318.3 349.6 Gross debt (PLN m) Cost/revenues 92.4% 93.0% 92.8% 93.0% 93.5% Operating cash flow D&A 1.0% 1.1%	EBITDA margin (%)	8.5%	7.9%	8.6%	9.0%	9.2%	Equity
Net debt / EBITDA (x) 0.75 0.15 -0.16 0.53 0.34 Net debt / Equity (x) 0.57 0.07 -0.07 0.23 0.14 Net debt / Assets (x) 0.23 0.04 -0.04 0.11 0.08 ROE (%) 64.6% 41.3% 34.1% 28.9% 24.8% Current liabilities ROA (%) 24.9% 19.9% 18.0% 14.5% 12.9% Trade payables Assumptions 2020 2021E 2022E 2023E 2024E Equity & liabilities Revenues 196.9 241.9 282.4 318.3 349.6 Gross debt (PLN m) products and services 141.9 195.0 236.5 273.3 305.5 Gross debt (PLN m) D&A 1.0% 1.1% 1.4% 2.1% 2.7% 2.1% 0.41.1 D&A 1.0% 1.1% 1.4% 2.1% 2.7% 0.41.1 D&A 1.0% 1.1% 1.4% 2.1% 2.7% 0.41.1	EBIT margin (%)	7.5%	6.9%	7.2%	7.0%	6.5%	Minorities
Net debt / Equity (x) 0.57 0.07 -0.07 0.23 0.14 Loans and borrowings Net debt / Assets (x) 0.23 0.04 -0.04 0.11 0.08 ROE (%) 64.6% 41.3% 34.1% 28.9% 24.8% Current liabilities ROA (%) 24.9% 19.9% 18.0% 14.5% 12.9% Trade payables Assumptions 2020 2021E 2022E 2023E 2024E Equity & liabilities Revenues 196.9 241.9 282.4 318.3 349.6 Gross debt (PLN m) products and services 141.9 195.0 236.5 273.3 305.5 goods and materials 55.0 46.9 45.9 45.0 44.1 Cost/revenues 92.4% 93.0% 93.3% 54.3% D&A Cast of materials and e 44.3% 50.1% 52.0% 53.3% 54.3% D&A Social benefits 1.5% 1.6% 1.5% 1.5% 1.6% 1.5% 1	Net margin (%)	5.9%	5.4%	5.8%	5.5%	5.2%	
Net debt / Assets (x) 0.23 0.04 -0.04 0.11 0.08 Other non-current liabilities ROE (%) 64.6% 41.3% 34.1% 28.9% 24.8% Current liabilities ROA (%) 24.9% 19.9% 18.0% 14.5% 12.9% Trade payables Assumptions 2020 2021E 2022E 2023E 2024E Equity & liabilities Revenues 196.9 241.9 282.4 318.3 349.6 Gross debt (PLN m) products and services 141.9 195.0 236.5 273.3 305.5 goods and materials 55.0 46.9 45.9 45.0 44.1 Cost/revenues 92.4% 93.0% 93.5% Departing cash flow D&A 1.0% 1.1% 1.4% 2.1% 2.7% D&A 1.0% 1.4% 2.1% Change in WC Taxes 0.3% 0.4% 0.4% 0.4% Other Social benefits 1.5% 1.5% 1.5%							
ROE (%) 64.6% 41.3% 34.1% 28.9% 24.8% Current liabilities ROA (%) 24.9% 19.9% 18.0% 14.5% 12.9% Trade payables Assumptions 2020 2021E 2022E 2023E 2024E Equity & liabilities Revenues 196.9 241.9 282.4 318.3 349.6 Gross debt (PLN m) products and services 141.9 195.0 236.5 273.3 305.5 Gross debt (PLN m) goods and materials 55.0 46.9 45.9 45.0 44.1 D&A 1.0% 1.1% 1.4% 2.1% 2.7% Net income Cost of materials and e 44.3% 50.1% 52.0% 53.3% 54.3% D&A Taxes 0.3% 0.4% 0.4% 0.4% 0.4% Other Social benefits 1.5% 1.6% 1.5% 1.5% 1.5% Change in intangible assets Other operating costs 0.1% 0.2% 0.2% 0.2%							-
ROA (%) 24.9% 19.9% 18.0% 14.5% 12.9% Trade payables ROIC (%) 39.0% 34.2% 34.7% 27.2% 21.4% Trade payables Assumptions 2020 2021E 2022E 2023E 2024E Gross adb torrowings Assumptions 2020 2021E 2022E 2023E 2024E Gross debt (PLN m) Products and services 141.9 195.0 236.5 273.3 305.5 Gross debt (PLN m) Odds and materials 55.0 46.9 45.9 45.0 44.1 Cost/revenues 92.4% 93.0% 93.5% Operating cash flow D&A 1.0% 1.1% 1.4% 2.1% 2.7% Net income D&A 0.0% 16.0% 16.2% 16.4% 16.5% Change in WC Taxes 0.3% 0.4% 0.4% 0.4% 0.4% Other Social benefits 1.5% 1.5% 1.5% 1.5% Change in intangible assets							
ROIC (%) 39.0% 34.2% 34.7% 27.2% 21.4% Loans and borrowings Other current liabilities Assumptions 2020 2021E 2022E 2023E 2024E Grass deb (PLN m) Products and services 141.9 195.0 236.5 273.3 305.5 Gross debt (PLN m) Cost/revenues 92.4% 93.0% 92.8% 93.0% 93.5% Net debt (PLN m) Cost/revenues 92.4% 93.0% 92.8% 93.0% 93.5% CASH FLOW (PLN m) D&A 1.0% 1.1% 1.4% 2.1% 2.7% Net income Cost of materials and e 44.3% 50.1% 52.0% 53.3% 54.3% D&A Taxes 0.3% 0.4% 0.4% 0.4% Other Investment cash flow Social benefits 1.5% 1.6% 1.5% 1.5% Change in intangible assets Charge in peake 02.6% 14.1% 12.0% 0.2% 0.2% Charge in equity Change in debt Payables							
Assumptions 2020 2021E 2022E 2023E 2024E Gother current liabilities Revenues 196.9 241.9 282.4 318.3 349.6 Gross debt (PLN m) products and services 141.9 195.0 236.5 273.3 305.5 Gross debt (PLN m) goods and materials 55.0 46.9 45.9 45.0 44.1 Cost/revenues 92.4% 93.0% 92.8% 93.0% 93.5% Operating cash flow D&A 1.0% 1.1% 1.4% 2.1% 2.7% Net income Cost of materials and e 44.3% 50.1% 52.0% 53.3% 54.3% D&A Cases 0.3% 0.4% 0.4% 0.4% Other Investment cash flow Social benefits 1.5% 1.6% 1.5% 1.5% Change in intangible assets Other operating costs 0.1% 0.2% 0.2% 0.2% Other Cash conv. (days) 68 66 65 64 63							
Assumptions 2020 2021E 2022E 2023E 2024E Equity & liabilities Revenues 196.9 241.9 282.4 318.3 349.6 Gross debt (PLN m) products and services 141.9 195.0 236.5 273.3 305.5 Gross debt (PLN m) goods and materials 55.0 46.9 45.9 45.0 44.1 Cost/revenues 92.4% 93.0% 92.8% 93.0% 93.5% Operating cash flow D&A 1.0% 1.1% 1.4% 2.1% 2.7% Net income Cost of materials and e 44.3% 50.1% 52.0% 53.3% 54.3% D&A Taxes 0.3% 0.4% 0.4% 0.4% 0.4% Other Salaries 8.9% 9.6% 9.1% 8.8% 8.8% Investment cash flow Cost of goods sold 20.6% 14.1% 12.0% 10.4% 9.2% Other Inventory 102 100 98 96 95	RUIC (%)	39.0%	34.2%	34.7%	27.2%	21,4%	0
Revenues 196.9 241.9 282.4 318.3 349.6 Gross debt (PLN m) products and services 141.9 195.0 236.5 273.3 305.5 goods and materials 55.0 46.9 45.9 45.0 44.1 Cost/revenues 92.4% 93.0% 92.8% 93.0% 93.5% Operating cash flow D&A 1.0% 1.1% 1.4% 2.1% 2.7% Net income Cost of materials and e 44.3% 50.1% 52.0% 53.3% 54.3% D&A External services 15.8% 16.0% 16.2% 16.4% 16.5% Change in WC Salaries 8.9% 9.6% 9.1% 8.8% 8.8% Investment cash flow Social benefits 1.5% 1.6% 1.5% 1.5% Change in intangible assets Other operating costs 0.1% 0.2% 0.2% 0.2% Change in equity Inventory 102 100 98 96 95 Change in debt </td <td>Assumptions</td> <td>2020</td> <td>2021F</td> <td>2022F</td> <td>2023E</td> <td>2024F</td> <td></td>	Assumptions	2020	2021F	2022F	2023E	2024F	
Products and services goods and materials 141.9 195.0 236.5 273.3 305.5 Net debt (PLN m) Cost of materials 55.0 46.9 45.9 45.0 44.1 CASH FLOW (PLN m) D&A 1.0% 1.1% 1.4% 2.1% 2.7% Description	· · · · · · · · · · · · · · · · · · ·						
goods and materials 55.0 46.9 45.9 45.0 44.1 Cost/revenues 92.4% 93.0% 92.8% 93.0% 93.5% Operating cash flow D&A 1.0% 1.1% 1.4% 2.1% 2.7% Net income Cost of materials and e 44.3% 50.1% 52.0% 53.3% 54.3% D&A External services 15.8% 16.0% 16.2% 16.4% 16.5% Change in WC Salaries 8.9% 9.6% 9.1% 8.8% 8.8% Investment cash flow Social benefits 1.5% 1.6% 1.5% 1.5% 1.5% Change in intangible assets Other operating costs 0.1% 0.2% 0.2% 0.2% Other Cash conv. (days) 68 66 65 64 63 Change in equity Inventory 102 100 98 96 95 Change in debt Receivables 8 8 7 7 Dividend							
Cost/revenues 92.4% 93.0% 92.8% 93.0% 93.5% Operating cash flow D&A 1.0% 1.1% 1.4% 2.1% 2.7% Net income Cost of materials and e 44.3% 50.1% 52.0% 53.3% 54.3% D&A External services 15.8% 16.0% 16.2% 16.4% 16.5% Change in WC Taxes 0.3% 0.4% 0.4% 0.4% 0.4% Other Salaries 8.9% 9.6% 9.1% 8.8% 8.8% Investment cash flow Social benefits 1.5% 1.6% 1.5% 1.5% Change in intangible assets Other operating costs 0.1% 0.2% 0.2% 0.2% Change in entangible assets Cost of goods sold 20.6% 14.1% 12.0% 10.4% 9.2% Other Inventory 102 100 98 96 95 Change in debt Receivables 8 8 7 7 Dividend O							
D&A 1.0% 1.1% 1.4% 2.1% 2.7% Net income Cost of materials and e 44.3% 50.1% 52.0% 53.3% 54.3% D&A External services 15.8% 16.0% 16.2% 16.4% 16.5% Change in WC Taxes 0.3% 0.4% 0.4% 0.4% 0.4% Other Salaries 8.9% 9.6% 9.1% 8.8% 8.8% Investment cash flow Social benefits 1.5% 1.6% 1.5% 1.5% Change in intangible assets Other operating costs 0.1% 0.2% 0.2% 0.2% Change in PP&E Cost of goods sold 20.6% 14.1% 12.0% 10.4% 9.2% Other Financial cash flow 102 100 98 96 95 Change in equity Inventory 102 100 98 95 Change in debt Change in debt Receivables 8 8 7 7 Dividend Other Payables 42 41 40 39 Other							CASH FLOW (PLN m)
Cost of materials and e 44.3% 50.1% 52.0% 53.3% 54.3% D&A External services 15.8% 16.0% 16.2% 16.4% 16.5% Change in WC Taxes 0.3% 0.4% 0.4% 0.4% 0.4% Other Salaries 8.9% 9.6% 9.1% 8.8% 8.8% Investment cash flow Social benefits 1.5% 1.6% 1.5% 1.5% Change in intangible assets Other operating costs 0.1% 0.2% 0.2% 0.2% Change in PP&E Cost of goods sold 20.6% 14.1% 12.0% 10.4% 9.2% Other External terration of the present of the	Cost/revenues	92.4%	93.0%	92.8%	93.0%	93.5%	Operating cash flow
External services 15.8% 16.0% 16.2% 16.4% 16.5% Change in WC Taxes 0.3% 0.4% 0.4% 0.4% 0.4% 0.4% 0.4% Salaries 8.9% 9.6% 9.1% 8.8% 8.8% Investment cash flow Social benefits 1.5% 1.6% 1.5% 1.5% Change in intangible assets Other operating costs 0.1% 0.2% 0.2% 0.2% Change in PP&E Cost of goods sold 20.6% 14.1% 12.0% 10.4% 9.2% Other Financial cash flow Kash 66 65 64 63 Change in equity Inventory 102 100 98 96 95 Change in debt Receivables 8 8 7 7 Dividend Payables 42 41 40 40 39 Other	D&A	1.0%	1.1%	1.4%	2.1%	2.7%	Net income
Taxes 0.3% 0.4% 0.4% 0.4% 0.4% Other Salaries 8.9% 9.6% 9.1% 8.8% 8.8% Investment cash flow Social benefits 1.5% 1.6% 1.5% 1.5% 1.5% Change in intangible assets Other operating costs 0.1% 0.2% 0.2% 0.2% Cash Change in PP&E Cost of goods sold 20.6% 14.1% 12.0% 10.4% 9.2% Other Financial cash flow Change in equity 102 100 98 96 95 Change in debt Receivables 8 8 8 7 7 Dividend Payables 42 41 40 40 39 Other	Cost of materials and e	44.3%	50.1%	52.0%	53.3%	54.3%	D&A
Salaries8.9%9.6%9.1%8.8%8.8%Investment cash flowSocial benefits1.5%1.6%1.5%1.5%1.5%Change in intangible assetsOther operating costs0.1%0.2%0.2%0.2%0.2%Change in PP&ECost of goods sold20.6%14.1%12.0%10.4%9.2%OtherFinancial cash flowCash conv. (days)6866656463Inventory102100989695Change in debtReceivables88877DividendPayables4241404039OtherChange in cash	External services	15.8%	16.0%	16.2%	16.4%	16.5%	Change in WC
Social benefits1.5%1.6%1.5%1.5%1.5%Change in intangible assetsOther operating costs0.1%0.2%0.2%0.2%0.2%Change in PP&ECost of goods sold20.6%14.1%12.0%10.4%9.2%Other Cash conv. (days) 6866656463Change in equityInventory102100989695Change in debtReceivables8877DividendPayables4241404039Other Change in cash	Taxes	0.3%	0.4%	0.4%	0.4%	0.4%	Other
Other operating costs Cost of goods sold 0.1% 0.2% 0.2% 0.2% 0.2% Change in PP&E Cost of goods sold 20.6% 14.1% 12.0% 10.4% 9.2% Other Cash conv. (days) 68 66 65 64 63 Change in equity Inventory 102 100 98 96 95 Change in debt Receivables 8 8 7 7 Dividend Other Payables 42 41 40 40 39 Other Change in cash Change in cash Change in cash Change in cash	Salaries	8.9%	9.6%	9.1%	8.8%	8.8%	Investment cash flow
Cost of goods sold 20.6% 14.1% 12.0% 10.4% 9.2% Other Cash conv. (days) 68 66 65 64 63 Change in equity Inventory 102 100 98 96 95 Change in debt Receivables 8 8 7 7 Dividend Payables 42 41 40 40 39 Other Change in cash							
Cash conv. (days)6866656463Inventory102100989695Change in equityReceivables8877DividendPayables42414039OtherChange in cash							0
Cash conv. (days) 68 66 65 64 63 Change in equity Inventory 102 100 98 96 95 Change in debt Receivables 8 8 7 7 Dividend Payables 42 41 40 39 Other Change in cash	Cost of goods sold	20.6%	14.1%	12.0%	10.4%	9.2%	
Inventory 102 100 98 96 95 Change in debt Receivables 8 8 8 7 7 Dividend Payables 42 41 40 40 39 Other Change in cash	Coop come (down)	~~~		65		62	
Receivables 8 8 7 7 Dividend Payables 42 41 40 40 39 Other Change in cash	-						
Payables 42 41 40 40 39 Other Change in cash	-						-
Change in cash							
-	- ayabics	42	41	40	40	55	
							Cash as of eop

	2019	2020	ZUZTE	ZUZZE	20235	20246
Revenues	142.3	196.9	241.9	282.4	318.3	349.6
Operating costs	-138.0	-182.0	-224.9	-262.2	-296.2	-326.8
D&A	-1.5	-1.9	-2.5	-4.0	-6.6	-9.5
Cost of materials and energy	-55.6	-87.3	-121.1	-146.9	-169.7	-189.7
External services	-21.1	-31.1	-38.6	-45.7	-52.1	-57.6
Taxes	-0.4	-0.5	-1.0	-1.2	-1.3	-1.4
Salaries	-13.0	-17.5	-23.1	-25.8	-28.1	-30.7
Social benefits	-2.5	-2.9	-3.9	-4.3	-4.7	-5.2
Other operating costs	-0.2	-0.3	-0.4	-0.4	-0.5	-0.6
Cost of goods sold	-43.6	-40.5	-34.2	-34.0	-33.1	-32.2
Other operating income/cost	-0.4	-0.2	-0.4	0.0	0.0	0.0
BITDA	5.5	16.6	19.2	24.2	28.7	32.3
BIT	3.9	14.7	16.6	20.3	22.2	22.8
inancial income (cost) net	-0.8	-0.4	-0.2	-0.1	-0.6	-0.4
Pre-tax profit	3.2	14.4	16.4	20.2	21.6	22.4
ncome tax	-0.7	-2.8	-3.3	-3.8	-4.1	-4.3
let profit	2.4	11.5	13.1	16.3	17.5	18.1
					.,	
BALANCE SHEET (PLN m)	2019	2020	2021E	2022E	2023E	2024E
lon-current assets	13.9	14.4	21.9	23.1	50.8	56.3
Goodwill and intangible assets	6.0	5.4	5.4	5.4	5.5	5.5
P&E	5.7	6.8	14.2	15.5	43.2	48.6
T investments	1.9	1.9	1.9	1.9	1.9	1.9
Other non-current assets	0.3	0.3	0.3	0.3	0.3	0.3
Current assets	25.3	39.0	56.3	80.1	87.3	86.7
nventories	19.4	31.8	38.6	45.0	50.4	55.2
rade receivables	4.2	3.8	4.7	5.5	6.2	6.8
Cash and equivalents	4.2 0.5	0.6	10.2	26.9	27.9	21.9
Other current assets	1.1	2.8	2.8	20.9	27.9	21.9
otal assets	39.2 13.9	53.4 21.8	78.3	103.3 54.1	138.1 66.7	143.0
iquity						79.5
Ainorities Provisions	0.0	0.0	0.0	0.0	0.0	0.0
	0.4	0.4	0.4	0.4	0.4	0.4
Non-current liabilities	2.3	2.7	2.7	2.7	2.7	2.7
oans and borrowings	2.3	2.7	2.7	2.7	2.7	2.7
Other non-current liabilities	0.0	0.0	0.0	0.0	0.0	0.0
Current liabilities	22.5	28.5	33.5	46.1	68.4	60.4
rade payables	9.5	13.1	16.0	18.6	20.9	22.8
oans and borrowings	11.2	10.3	10.3	20.3	40.3	30.3
Other current liabilities	1.8	5.1	7.2	7.2	7.2	7.2
quity & liabilities	39.2	53.4	78.3	103.3	138.1	143.0
Fross debt (PLN m)	13.6	13.0	13.0	23.0	43.0	33.0
let debt (PLN m)	13.1	12.4	2.8	-3.9	15.2	11.1
	204.0	2020	20245	20225	20225	20245
CASH FLOW (PLN m)	2019	2020	2021E	2022E	2023E	2024E
Operating cash flow	3.1	7.2	13.7	16.3	21.2	25.0
let income	2.4	11.5	13.1	16.3	17.5	18.1
0&A	1.5	1.9	2.9	4.0	6.6	9.5
Change in WC	-2.2	-6.6	-4.9	-4.5	-3.9	-3.4
Other	1.3	0.3	2.5	0.6	1.1	0.8
nvestment cash flow	-1.0	-1.4	-10.4	-5.2	-34.3	-14.9
hange in intangible assets	0.6	0.6	-0.6	-0.6	-0.6	-0.6
Change in PP&E	-3.2	-3.0	-9.8	-4.5	-33.7	-14.3
Dther	1.6	1.0	0.0	0.0	0.0	0.0
inancial cash flow	-1.8	-5.7	6.4	5.5	14.0	-16.1
hange in equity	0.0	0.0	9.3	0.0	0.0	0.0
Change in debt	0.0	-0.8	0.0	10.0	20.0	-10.0
Dividend	0.0	-2.1	-2.5	-3.9	-4.9	-5.2
Other	-1.8	-2.7	-0.3	-0.6	-1.1	-0.8
Change in cash	0.3	0.0	9.6	16.7	1.0	-5.9
Cash as of eop	0.5	0.6	10.2	26.9	27.9	21.9

Source: Company data, IPOPEMA Research

Table of Contents

Valuation	. 4
DCF valuation	.4
DDM valuation	. 5
Peer comparison	. 5
Financial forecasts	. 6
Risk factors	. 7

Valuation

We value SFD using the discounted cash flow method (75% weight) and discounted dividend method (weight of 25%). We add a multiples valuation for presentation purpose only.

Figure 2.	SFD -	Valuation summary	
-----------	-------	-------------------	--

Valuation method	Weight (%)	FV (PLN/share)
DCF valuation	75%	5.77
DDM valuation	25%	4.73
Peer comparison	0%	4.70
Fair value		5.51
Current price		3.90
Upside/downside		41%

Source: Company, IPOPEMA Research

DCF valuation

We base our DCF valuation on our free cash flow forecasts for 2021-31E. We apply a risk-free rate of 3.3-3.5% in forecasted years and 3.5% in terminal, equity risk premium at 5.0% and unlevered beta of 1.3x and assume a terminal growth rate of 3.0%.

Figure 3. SFD – DCF valuation (PLNm)

	2021E	2022E	2023E	2024E	2025E	2026E	2027E	2028E	2029E	2030E	2031E	τv
Revenues	241.9	282.4	318.3	349.6	376.5	405.7	437.4	470.7	506.9	546.2	588.9	
EBITDA	19.2	24.2	28.7	32.3	35.0	38.2	41.4	45.7	50.4	55.6	61.3	
EBIT	16.6	20.3	22.2	22.8	24.6	26.1	27.1	31.1	33.8	39.5	46.3	
Tax on EBIT	-3.2	-3.8	-4.2	-4.3	-4.7	-5.0	-5.1	-5.9	-6.4	-7.5	-8.8	
NOPAT	13.5	16.4	17.9	18.5	19.9	21.1	21.9	25.2	27.4	32.0	37.5	
D&A	2.9	4.0	6.6	9.5	10.4	12.1	14.4	14.6	16.6	16.1	15.0	
Change in WC	-4.9	-4.5	-3.9	-3.4	-2.9	-3.2	-3.5	-3.7	-4.0	-4.3	-4.7	
Capex	-10.4	-5.2	-34.3	-14.9	-9.7	-15.6	-17.3	-14.6	-14.9	-17.0	-16.4	
FCF	1.1	10.7	-13.7	9.7	17.7	14.4	15.5	21.5	25.1	26.8	31.4	34.0
Discount factor (%)	100%	91%	83%	75%	69%	62%	57%	52%	47%	43%	39%	
FCF PV (PLNm)	1.1	9.7	-11.3	7.3	12.1	9.0	8.8	11.1	11.8	11.5	12.2	
FCF PV 2021-31E (PLNm)	83											
Residual growth rate (%)	3.0%											
Discounted residual value (PLNm)	186								V	VACC (%)		
EV (PLNm)	269							9.1%	9.6%	10.1%	10.6%	11.1%
Dividend paid (PLNm)	3					_	2.0%	5.28	5.26	5.24	5.23	5.21
Net debt (PLNm)	12					Residual	2.5%	5.52	5.51	5.49	5.47	5.45
Equity value (PLNm)	254					growth	3.0%	5.80	5.78	5.77	5.74	5.72
Number of shares(m)	44.0					rate (%)	3.5%	6.12	6.10	6.08	6.06	6.04
FV (PLN)	5.77						4.0%	6.50	6.47	6.45	6.43	6.40

Source: Company, IPOPEMA Research

Figure 4. SFD – WACC calculation

WACC	2021E	2022E	2023E	2024E	2025E	2026E	2027E	2028E	2029E	2030E	2031E	тν
RFR	3.3%	3.4%	3.3%	3.3%	3.3%	3.3%	3.5%	3.5%	3.5%	3.5%	3.5%	3.5%
Beta leveraged	1.6	1.7	2.0	1.7	1.6	1.4	1.4	1.4	1.4	1.4	1.4	1.4
Risk premium	5.0%	5.0%	5.0%	5.0%	5.0%	5.0%	5.0%	5.0%	5.0%	5.0%	5.0%	5.0%
Cost of Equity	11.4%	12.1%	13.2%	12.0%	11.1%	10.4%	10.5%	10.4%	10.4%	10.3%	10.3%	10.3%
Debt risk premium	2.0%	2.0%	2.0%	2.0%	2.0%	2.0%	2.0%	2.0%	2.0%	2.0%	2.0%	2.0%
Tax rate	19.0%	19.0%	19.0%	19.0%	19.0%	19.0%	19.0%	19.0%	19.0%	19.0%	19.0%	0.0%
After tax cost of debt	4.3%	4.3%	4.3%	4.3%	4.3%	4.3%	4.4%	4.4%	4.4%	4.4%	4.4%	5.5%
% D	23.8%	29.8%	39.2%	29.3%	19.7%	10.7%	9.4%	8.3%	7.3%	6.4%	5.6%	5.6%
% E	76.2%	70.2%	60.8%	70.7%	80.3%	89.3%	90.6%	91.7%	92.7%	93.6%	94.4%	94.4%
WACC	9.7%	9.8%	9.7%	9.8%	9.8%	9.7%	9.9%	9.9%	9.9%	9.9%	9.9%	10.1%

Source: Company, IPOPEMA Research

We value SFD using the DDM method based on our financial forecasts and assumptions regarding the dividend payout ratio. The company has established its dividend policy for 2020-22 with a dividend payout ratio of at least 20%. In the forecasted years, we assume a dividend payout ratio of 30%.

Figure 5. SFD – DDM valuation (PLNm)

	2021E	2022E	2023E	2024E	2025E	2026E	2027E	2028E	2029E	2030E	2031E	τv
Net profit (PLNm)	13.1	16.3	17.5	18.1	19.8	21.2	22.1	25.6	28.0	32.9	38.7	39.9
change y/y	14%	25%	7%	4%	9%	7%	5%	16%	10%	17%	18%	3%
Pay-out ratio (%)	22%	30%	30%	30%	30%	30%	30%	30%	30%	30%	30%	88%
Dividend paid (PLNm)	2.5	3.9	4.9	5.2	5.4	5.9	6.4	6.6	7.7	8.4	9.9	34.0
Equity (PLNm)	41.7	54.1	66.7	79.5	93.9	109.1	124.9	143.8	164.2	188.7	217.6	222.5
ROE (%)	41%	34%	29%	25%	23%	21%	19%	19%	18%	19%	19%	24%
Cost of equity (%)	11%	12%	13%	12%	11%	10%	11%	10%	10%	10%	10%	10%
Discount factor (%)	99%	89%	77%	71%	65%	61%	55%	50%	45%	41%	37%	
Discounted dividend payment (PLNm)	0.0	3.5	3.8	3.7	3.5	3.6	3.5	3.3	3.5	3.5	3.7	
Growth rate (%)	3%											
Discounted dividend payments 2021-30E (PLNm)	36											
Terminal value (PLNm)	462											
Discounted terminal value (PLNm)	173											
Equity value (PLNm)	208											
Number of shares (m)	44.0											
FV/share (PLN)	4.73											

Source: Company, IPOPEMA Research

Peer comparison

We present a multiple valuation by comparing SFD to retail and e-commerce companies, based on the P/E, EV/EBITDA and EV/Sales multiples. Due to different business models and scale of operation, we give 0% weight to the method.

Figure 6. SFD – peer comparison

Company	mCap P/E (x)				EV/EBITDA (x)			EV/Sales (x)		
	(PLNm)	2021E	2022E	2023E	2021E	2022E	2023E	2021E	2022E	2023E
Xiamen Kingdomway Group	12,351	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
Natural Food International Holding	607	14.0	9.0	7.7	4.0	2.5	1.8	0.2	0.2	0.1
NewTree Co.	724	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
Naturhouse Group	531	8.7	8.3	7.7	4.2	4.0	3.6	1.5	1.4	1.3
Bellring Brands	13,929	26.4	24.1	19.0	29.4	26.0	22.4	3.1	2.8	2.5
Usana Health Sciences	7,995	16.8	16.2	15.5	n.a.	n.a.	n.a.	1.4	1.4	1.4
Herbalife Nutrition	17,092	7.7	7.4	6.3	n.a.	n.a.	n.a.	1.1	1.1	1.1
Median		14.0	9.0	7.7	4.2	4.0	3.6	1.4	1.4	1.3
SFD		13.1	10.5	9.8	9.1	6.9	6.5	0.7	0.6	0.6
Premium/discount (%)		-6%	17%	27%	116%	74%	81%	-50%	-57%	-54%
Implied FV/share (PLN)		4.2	3.3	3.1	1.8	2.3	2.0	7.8	8.9	8.9
Average implied FV/share (PLN)		4.70								

Source: Bloomberg, IPOPEMA Research

- Xiamen Kindomway Group produces and sells fortified food and feed additives.
- **Natural Food**, through its subsidiaries, processes and sells natural health food products made of grains, beans, nuts, dried fruits, and other natural ingredients.
- **NewTree** manufactures and sells collagen health food, weight loss health products, stomach health food, and others.
- **Naturhouse** provides retail sale of health related products promoting healthy eating, medicinal herbs and natural cosmetics.
- Bellring Brands produces nutritional items such as protein shakes, powders, bars.
 - **Usana Health Sciences** develops, manufactures, and markets nutritionals, personal care, and weight management products.
- Herbalife Nutrition manufactures and sells weight management, meals and snacks, sports and fitness, energy, and nutritional products, personal care products.

ipopema

Financial forecasts

Figure 7. SFD – Change of financial forecasts (PLNm)

		2021E			2022E			2023E	
	Current	Previous	Change	Current	Previous	Change	Current	Previous	Change
Revenues	241.9	235.1	3%	282.4	274.4	3%	318.3	308.9	3%
sale of products and services	195.0	188.7	3%	236.5	229.0	3%	273.3	264.4	3%
sale of goods and materials	46.9	46.3	1%	45.9	45.4	1%	45.0	44.5	1%
Operating costs	-224.9	-216.3	4%	-262.2	-251.8	4%	-296.2	-284.7	4%
D&A	-2.5	-2.6	-2%	-4.0	-4.5	-13%	-6.6	-7.8	-15%
Cost of materials and energy	-121.1	-113.6	7%	-146.9	-137.8	7%	-169.7	-159.1	7%
External services	-38.6	-38.0	2%	-45.7	-44.9	2%	-52.1	-51.1	2%
Taxes	-1.0	-1.2	-19%	-1.2	-1.4	-19%	-1.3	-1.6	-19%
Salaries	-23.1	-22.9	1%	-25.8	-25.5	1%	-28.1	-27.9	1%
Social benefits	-3.9	-3.9	-1%	-4.3	-4.4	-1%	-4.7	-4.8	-1%
Other operating costs	-0.4	-0.2	138%	-0.4	-0.2	138%	-0.5	-0.2	138%
Cost of goods sold	-34.2	-34.0	1%	-34.0	-33.1	3%	-33.1	-32.2	3%
Profit from operations	17.0	18.7	-9%	20.3	22.6	-10%	22.2	24.3	-9%
Other operating profit	0.4	0.2	124%	0.0	0.0	n.m.	0.0	0.0	n.m.
Other operating costs	-0.8	-0.5	55%	0.0	0.0	n.m.	0.0	0.0	n.m.
EBITDA	19.2	21.0	-9%	24.2	27.1	-11%	28.7	32.0	-10%
EBIT	16.6	18.4	-10%	20.3	22.6	-10%	22.2	24.3	-9%
Financial income	0.1	0.2	-48%	0.5	0.4	12%	0.5	0.5	4%
Financial cost	-0.3	-0.6	-46%	-0.6	-0.6	0%	-1.1	-1.1	0%
Pre-tax profit	16.4	18.0	<i>-9%</i>	20.2	22.5	-10%	21.6	23.7	-9%
Income tax	-3.3	-3.5	-6%	-3.8	-4.3	-10%	-4.1	-4.5	-9%
Net profit	13.1	14.5	-9%	16.3	18.2	-10%	17.5	19.2	-9%

Source: Company, IPOPEMA Research

As major risk factors we point to:

- **Risk related to the cost of materials.** The company offers its own-branded and thirdparty-brand products, thus potential delays in deliveries or any increase in the cost of materials may result in higher product prices or lower margins.
- **Risk related to the competitive outlook.** The OTC drug and supplement market in Poland is still highly fragmented, thus any potential tightening of competitions, market consolidation, and lower positioning of SFD's websites on search platforms may negatively affect the company's revenue generation.
- **Risk related to health protection.** Potential changes in regulations may affect trade conditions and product offer. We note that the European Union is currently planning to introduce minimum and maximum doses of vitamins and minerals, which might negatively affect the company's operations (new regulations are planned to be introduced in 1Q24).
- **Risk related to the macroeconomic situation.** Potential slowdown might negatively affect demand on SFD's products and services.
- **Risk related to expansion on foreign markets.** The company has decided to launch its e-commerce platforms in Czechia and Slovakia, what might negatively affect operating costs (mainly in terms of logistics and marketing).
- **Risk related to FX rates.** The company's results depend on EUR and USD currencies (purchase of goods from the USA and sale of products in European countries).

This document has been prepared by IPOPEMA Securities S.A. with its registered seat in Warsaw, Próżna 9, 00-107 Warsaw, Poland, entered into the Register of Entrepreneurs of the National Court Register maintained by the District Court for the City of Warsaw, XII Commercial Division of the National Court Register under entry number KRS 0000230737, the initial capital and paid capital in the amount of PLN 2.993.783,60, NIP 5272468122, www.ipopema.pl. IPOPEMA Securities S.A. is supervised by the Polish Financial Supervision Authority (Komisja Nadzoru Finansowego), Piękna 20, 00-549 Warsaw, Poland.

This document was prepared by IPOPEMA Securities S.A. for information purposes only. This document is addressed to IPOPEMA Securities S.A. clients entitled to receive it on the basis of contracts for the provision of services. This document, using mass media distribution channels, may also reach other investors. It has been produced independently of the company mentioned in this document and any forecasts, opinions and expectations are entirely those of IPOPEMA Securities S.A. Unless otherwise specified, the estimates and opinions contained in the document constitute an independent assessment of IPOPEMA Securities S.A. analysts preparing the document as of the date of issuing the document.

IPOPEMA Securities S.A. prepared this document with the preservation of all adequate diligence, thoroughness and reliability on the basis of publicly available information which IPOPEMA Securities S.A. believes to be reliable. The sources of data are primarily: Bloomberg, Reuters, EPFR, Polska Agencja Prasowa, WSE, Główny Urząd Statystyczny, Narodowy Bank Polski, financial press, online financial and economic services. While due diligence has been taken by IPOPEMA Securities S.A. to ensure that the facts stated herein are accurate and that any forecasts, opinions and expectations contained herein are fair and reasonable, IPOPEMA Securities S.A. has not independently verified all the information given in this document. Accordingly, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information and opinions contained in this document. The opinions expressed in the document can change without notice and IPOPEMA Securities S.A. is under no obligation to keep these opinion current. None of the IPOPEMA Securities S.A. or any other person accepts any liability whatsoever for any loss howsoever arising from any use of this document or its contents or otherwise arising in connection therewith provided that IPOPEMA Securities S.A. has been exercised due diligence and integrity during its preparation. This document may be sent to the mass media, however its copying or publishing in whole or in part as well as dissemination of information enclosed to it is allowed only with prior permission of IPOPEMA Securities S.A. This document nor any copy hereof is not to be distributed directly or indirectly in the United States, Australia, Canada or Japan, subject to the following section.

Important disclosures for U.S. Persons: Auerbach Grayson & Company Inc. may distribute this document in the U.S. This document is provided for distribution to Major U.S. Institutional Investors in reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended and may not be furnished to any other person in the U.S. Each Major U.S. Institutional Investor that receives this document shall not distribute or provide it to any other person. Under no circumstances should any U.S. recipient of this document effect any transaction to buy or sell securities or related financial instruments through IPOPEMA Securities S.A. Any U.S. recipient of this document wishing to effect any transaction to buy or sell securities or related financial instruments based on the information provided in this document should do so only through Auerbach Grayson & Company Inc. 25 West 45th Street, Floor 16, New York, NY 10036 U.S. which is a registered broker dealer in the U.S. IPOPEMA Securities S.A. and a registered brokerdealer in the U.S. and, therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. IPOPEMA Securities S.A. and its research analysts are not associated persons of Auerbach Grayson & Company, nor are they affiliated with Auerbach Grayson & Company. The author of this document whose name appears in this document is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"), is not subject to the SEC rules on research analysts and is not subject FINRA's rules on debt research neaplysts and debt research neaplysts and equity research analysts and equity research analysts and equity research reports. U.S. recipients should take into account that information on non-U.S. securities or related financial instruments discussed in this document may be limited. The financial instruments of non-U.S. issuers may not be registered with, or be subject to the r

This document does not constitute any offer to sell or induce any offer to buy or sell any financial instruments, cannot be relied on in connection with any contract or liability and does not constitute advertising or promotion of a financial instrument or the company. Investment decisions should only be made on the basis of a prospectus or other publicly available information and materials.

The document was prepared without taking into account the needs and situation of the recipients of the document. When preparing the document, IPOPEMA Securities S.A. does not examine the recipient's investment objectives, risk tolerance level, time horizon and financial standing of the investors. The company or the financial instruments discussed in the document may not be suitable for the users of the document, i.e. it may not be suitable for the specific objectives and time horizon or the financial istruments discussed in the document cannot be regarded as a substitute for obtaining investment advice service. The value of financial instruments may fluctuate, including declines. Changes in FX rates may have an adverse effect on the value of investments. The investment in financial instruments is linked to investment risks including loss of entire or part of the invested capital. Past performance is not necessarily indicative of future results. IPOPEMA Securities S.A. points out that the price of financial instruments is affected by many different factors that are or may be independent of the company and the results of its operations. These include, among others changing economic, legal, political and tax conditions. IPOPEMA Securities S.A. may have issued in the past or may issue other documents in the future, presenting other conclusions, not consistent with those presented herein document. Such documents reflect different assumptions, points of view and analytical methods adopted by the analysts preparing them.

Investors should be aware that IPOPEMA Securities S.A. or its related entities may have a conflict of interest that could affect this document's objectivity. The investor should assume that IPOPEMA Securities S.A. or its related entities may provide services in favour of the company and obtain remuneration on this account. They may also have another financial interest with respect to the company. IPOPEMA Securities S.A. or its related entities may seek to do business with the company or other entities mentioned in this document. IPOPEMA Securities S.A. has an organizational structure and internal regulations in place to ensure that the client's interests are not compromised in the event of a conflict of interest, in relation to preparing this document. Conflict of interest management policy is available on the website at https://www.ipopemasecurities.pl/analizy-i-rekomendacje.pl62. This document was prepared irrespective and independently of the interests of IPOPEMA Securities S.A., the company that is the subject of this document and holder of financial instrument issued by aforementioned company. IPOPEMA Securities S.A., its shareholders, employees and associates may hold long or short positions in the company's financial instruments.

Information on the conflict of interest arising in connection with the preparation of the document (if any) is provided below.

On the order of the Warsaw Stock Exchange S.A. ("WSE"), IPOPEMA Securities S.A. creates analytical materials for the following companies: ATM Grupa S.A., Mirbud S.A., ML System S.A., OncoArendi Therapeutics S.A., PointPack S.A., SFD S.A., Synektik S.A., Fabryka Farb i Lakierów Śnieżka S.A., Ultimate Games S.A., Vigo System S.A. The WSE has proprietary copyrights to these materials. For the preparation of IPOPEMA Securities S.A. receives remuneration from the WSE. Information on the program is available on the website https://www.gpw.pl/gpwpa.

On the order of the Bursa de Valori Bucuresti S.A. ("BVB"), IPOPEMA Securities S.A. creates analytical materials for the following companies: Bittnet Systems S.A. and Impact Developer & Contractor S.A. The BVB has proprietary copyrights to these materials. For the preparation of IPOPEMA Securities S.A. receives remuneration from the BVB.

IPOPEMA Securities S.A. uses a number of valuation methodologies including discounted cash flows models (such as discounted operating earnings or dividend discount model), and earnings and cash-flow based models, which are often related to comparisons with selected peer companies. Cash flow models encapsulate the cash streams forecast to flow to a company, and are widely used in the investment industry. Peer comparisons factor in amongst other factors, differential growth rates, and indicate how expensive one company might appear relative to a chosen comparator. The subjective opinions of the report's author or authors, formed by their knowledge and experience, play a significant role in the valuation. Also included are assumptions on numerous economic variables, particularly interest rates, inflation and exchange rates and varying these assumptions could results in significantly different opinions. The strength of the earnings and cash flow based models is the closer attention to a company on a standalone basis, and tying the valuation to its fundamental value. The weakness of such method is the number of assumptions, which need to be adopted and resulting sensitivity to those assumptions. The peer comparisons methods are less dependent on the analyst's judgment as to the individual parameters, however the problem with this method appears when the peer comparator is over- or undervalued. Moreover, leading multiples (based on the future earnings, book values, operating profit or cash flows) include an analyst's estimate of those values.

This document was not transferred to the company prior to its publication. This document was prepared according to the author's own view, assumptions and knowledge.

Recommendations issued by IPOPEMA Securities S.A. they are valid for a period of 12 months from the date of issue, unless they are updated during this period. IPOPEMA Securities S.A. updates the issued recommendations depending on the market situation and subjective analysts' assessment. In the last 12 months IPOPEMA Securities S.A. has not prepared any recommendation concerning the company.

This document is an investment research within the meaning of Art. 36 par. 1 of the Commission Delegated Regulation (EU) 2017/565.

List of all recommendations regarding any financial instrument or issuer that have been disseminated within the last 12 months by IPOPEMA Securities S.A. is available on the website at https://www.ipopemasecurities.pl/analizy-i-rekomendacje.p162.

The date and the time stated on the front page is the date of the preparation of this document. The price used throughout the recommendation to calculate adequate ratios is the "last" price stated on the front page of this document.

The definitions of terms used in the document include: NII – Net interest income – interest income minus interest expense.

Net F&C – Net fee and commission income – fee and commission income minus fee and commission expense.

LLP - loan loss provisions - an expense set aside as an allowance for bad loans.

NPL - non-performing loan - loans that are in default or close to be in default.

Cost/Income – operating expenses divided by total banking revenue.

ROE - return on equity - net income (or adjusted net income) divided by the average shareholders' equity.

ROA – return on assets – net income (or adjusted net income) divided by the average assets.

EBIT – earnings before interests and tax.

EBITDA – earnings before interests, tax, depreciation and amortization.

EPS - earnings per share - the net income (or adjusted net income divided by the number of shares outstanding.

P/E – price to earnings ratio – price divided by earnings per share. PEG – P/E ratio divided by the annual EPS growth, usually over a certain period of time.

CAGR – compound annual growth rate.

BVPS - book value per share, the book value of the Company's equity divided by the number of shares outstanding.

P/BV - price to book value - price divided by the BVPS.

DPS - dividend per share - dividend of a given year divided by the number of shares outstanding.

DY – dividend yield – dividend of a given year divided by the current price.

DDM – dividend discount model – a fundamental method of valuation based on the assumption that the value of stock equals the sum of all discounted future dividends. FV – Fair Value, calculated based on valuation methods outlined in the document.

The author of this document has no conflict of interest with the company that is the subject of this document. The point of view expressed in the document reflects the personal opinion of the author of the document on the analyzed company and its financial instruments. Investors should be aware that flexible part of the author's compensation may depend on general financial performance of IPOPEMA Securities S.A.

IPOPEMA Securities S.A. shall act with due diligence, honestly, fairly, professionally and in accordance with the provisions of the applicable law.

IPOPEMA Securities S.A. does not guarantee achieving the investor's investment objective, the performance of company or prospective prices referred to herein.

When applying ratings for companies following criteria are used with regards to the difference between IPOPEMA's FV and company's price at the date of recommendation:

Rating	Difference between FV and price at recommendation
Buy	Above 10%
Hold	In between (and including) -10% and 10%
Sell	Below -10%

IPOPEMA Research - Distribution by rating category (July 1 – September 30, 2021)

	Number	%
Buy	52	74%
Hold	14	20%
Sell	4	6%
Total	70	100%

Rating History – SFD				
Date	Recommendation	Fair Value	Price at recommendation	Author
07/09/2021	BUY	PLN 6.50	PLN 4.69	Marek Szymański
13/12/2021	BUY	PLN 5.51	PLN 3.90	Marek Szymański